**Pseudomyxoma Peritonei Syndrome of Appendiceal Origin: An Overview**

Carol Brueggen, MS, RN, APRN-BC, AOCNS®, Gayle Baird, MS, RN, APRN-BC, and Allison Meisheid, MS, RN, OCN®

Pseudomyxoma peritonei (PMP) syndrome is an uncommon, slowly progressive condition that usually arises from perforation of an adenoma in the appendix. PMP syndrome is characterized by mucin accumulation in the peritoneal cavity. Mucinous implants are found on all peritoneal surfaces and the omentum. PMP syndrome rarely metastasizes outside the abdominal cavity but remains a fatal illness as the space in the abdomen and pelvis required for normal function of the gastrointestinal tract becomes filled with copious amounts of the mucinous tumor. Treatment options include observation, aggressive debulking surgery, intraperitoneal chemotherapy, radiotherapy, and mucolytic agents.

### At a Glance

- Pseudomyxoma peritonei (PMP) syndrome is an uncommon, slowly progressive disease characterized by large amounts of mucinous ascites, which accumulate in the abdomen and pelvis. Five-year survival rates for PMP syndrome range from 75%–86%.
- Treatment options for PMP syndrome are multimodal and include observation, aggressive debulking surgery, intraperitoneal chemotherapy, radiotherapy, and mucolytic agents.
- Treating PMP syndrome with intraperitoneal chemotherapy allows higher concentrations of cytotoxic agents to be administered directly into abdominal and pelvic surfaces where the tumor is located without producing toxic systemic levels.

PMP syndrome should be applied only to histologically benign peritoneal tumors that are slow growing and associated most commonly with appendiceal mucinous adenoma. Pathologically, mucinous lesions are classified as DPAM or adenomucinosis (Sugarbaker et al., 1997). This article will focus on the DPAM pathologic classification.

---

Digital Object Identifier: 10.1188/07.CJON.525-532